Exclusive outtakes from industry leaders
Audio – Amgen sees no need to undercut Erbitux on pricing to gain market share
Amgen’s vice president of oncology tells Reuters that undercutting Erbitux on pricing was not necessary to help its own cancer drug Vectibix gain market share.
Post Your Comment
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/